{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T14:25:18Z","timestamp":1751379918488},"reference-count":27,"publisher":"Japanese Circulation Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2022,12,9]]},"DOI":"10.1253\/circrep.cr-22-0110","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T22:12:45Z","timestamp":1669414365000},"page":"579-587","source":"Crossref","is-referenced-by-count":1,"title":["External Validation of the Kumamoto Criteria in Transthyretin Amyloid Cardiomyopathy Screening\u3000\u2015 A Retrospective Cohort Study \u2015"],"prefix":"10.1253","volume":"4","author":[{"given":"Yukihiro","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshige","family":"Murata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonari","family":"Kiriyama","sequence":"additional","affiliation":[{"name":"Department of Radiology, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinobu","family":"Kunugi","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Hachisuka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Tama-Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Imori","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Yodogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-ki","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitaro","family":"Kodani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Tama-Nagayama Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Analytic Human Pathology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. <i>Circulation<\/i> 2012; 126: 1286\u20131300.","DOI":"10.1161\/CIRCULATIONAHA.111.078915"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Westin O, Butt JH, Gustafsson F, Schou M, Salomo M, K\u00f8ber L, et al. Two decades of cardiac amyloidosis: A Danish nationwide study. <i>JACC CardioOncol<\/i> 2021; 3: 522\u2013533.","DOI":"10.1016\/j.jaccao.2021.05.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. <i>Eur Heart J<\/i> 2015; 36: 2585\u20132594.","DOI":"10.1093\/eurheartj\/ehv338"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Staron A, Connors LH, Ruberg FL, Mendelson LM, Sanchorawala V. A new era of amyloidosis: The trends at a major US referral centre. <i>Amyloid<\/i> 2019; 26: 192\u2013196.","DOI":"10.1080\/13506129.2019.1640672"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. <i>Circulation<\/i> 2016; 133: 2404\u20132412.","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, et al. Multicenter study of planar technetium 99 m pyrophosphate cardiac imaging: Predicting survival for patients with ATTR cardiac amyloidosis. <i>JAMA Cardiol<\/i> 2016; 1: 880\u2013889.","DOI":"10.1001\/jamacardio.2016.2839"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99 m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. <i>Circ Cardiovasc Imaging<\/i> 2013; 6: 195\u2013201.","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Marume K, Takashio S, Nishi M, Hirakawa K, Yamamoto M, Hanatani S, et al. Combination of commonly examined parameters is a useful predictor of positive (99 m)Tc-labeled pyrophosphate scintigraphy findings in elderly patients with suspected transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2019; 83: 1698\u20131708.","DOI":"10.1253\/circj.CJ-19-0255"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ochi Y, Kubo T, Baba Y, Ueda M, Miyagawa K, Noguchi T, et al. Validation of the Kumamoto criteria for prediction of (99 m) technetium pyrophosphate scintigraphy positivity as a strategy for diagnosis of transthyretin cardiac amyloidosis: A retrospective cohort study in Kochi. <i>J Cardiol<\/i> 2021; 77: 124\u2013130.","DOI":"10.1016\/j.jjcc.2020.06.019"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kubota T, Sunagawa G, Nagatomo D, Tsutsui Y, Tsutsui H. Utility of Kumamoto criteria in diagnosing transthyretin cardiac amyloidosis in real-world practice. <i>Circ J<\/i> 2020; 84: 680.","DOI":"10.1253\/circj.CJ-19-0992"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsutsui Y, Kubota T, Kato S, Nozoe M, Suematsu N, Okabe M, et al. Utility of (99 m)Tc-pyrophosphate scintigraphy in diagnosing transthyretin cardiac amyloidosis in real-world practice. <i>Circ Rep<\/i> 2019; 1: 277\u2013285.","DOI":"10.1253\/circrep.CR-19-0015"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2015; 28: 1\u201339.e14.","DOI":"10.1016\/j.echo.2014.10.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99 mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. <i>J Am Coll Cardiol<\/i> 2005; 46: 1076\u20131084.","DOI":"10.1016\/j.jacc.2005.05.073"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2 \u2013 evidence base and standardized methods of imaging. <i>J Nucl Cardiol<\/i> 2019; 26: 2065\u20132123.","DOI":"10.1007\/s12350-019-01760-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Inomata T, Tahara N, Nakamura K, Endo J, Ueda M, Ishii T, et al. Diagnosis of wild-type transthyretin amyloid cardiomyopathy in Japan: Red-flag symptom clusters and diagnostic algorithm. <i>ESC Heart Fail<\/i> 2021; 8: 2647\u20132659.","DOI":"10.1002\/ehf2.13473"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2021; 42: 1554\u20131568.","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Witteles RM, Bokhari S, Damy T, Elliott PM, Falk RH, Fine NM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. <i>JACC Heart Fail<\/i> 2019; 7: 709\u2013716.","DOI":"10.1016\/j.jchf.2019.04.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lauppe RE, Liseth Hansen J, Gerdesk\u00f6ld C, Rozenbaum MH, Strand AM, Vakevainen M, et al. Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden. <i>Open Heart<\/i> 2021; 8: e001755.","DOI":"10.1136\/openhrt-2021-001755"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Aus dem Siepen F, Hein S, Prestel S, Baumg\u00e4rtner C, Sch\u00f6nland S, Hegenbart U, et al. Carpal tunnel syndrome and spinal canal stenosis: Harbingers of transthyretin amyloid cardiomyopathy? <i>Clin Res Cardiol<\/i> 2019; 108: 1324\u20131330.","DOI":"10.1007\/s00392-019-01467-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sekijima Y, Yazaki M, Ueda M, Koike H, Yamada M, Ando Y. First nationwide survey on systemic wild-type ATTR amyloidosis in Japan. <i>Amyloid<\/i> 2018; 25: 8\u201310.","DOI":"10.1080\/13506129.2017.1409706"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, et al. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: A prospective, observational cohort study. <i>Circulation<\/i> 2016; 133: 282\u2013290.","DOI":"10.1161\/CIRCULATIONAHA.115.018852"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zadok OIB, Eisen A, Shapira Y, Monakier D, Iakobishvili Z, Schwartzenberg S, et al. Natural history and disease progression of early cardiac amyloidosis evaluated by echocardiography. <i>Am J Cardiol<\/i> 2020; 133: 126\u2013133.","DOI":"10.1016\/j.amjcard.2020.07.050"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Grodin JL, Maurer MS. The truth is unfolding about transthyretin cardiac amyloidosis. <i>Circulation<\/i> 2019; 140: 27\u201330.","DOI":"10.1161\/CIRCULATIONAHA.119.041015"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, et al. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. <i>J Am Coll Cardiol<\/i> 2016; 68: 1014\u20131020.","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: A common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. <i>Amyloid<\/i> 2016; 23: 58\u201363.","DOI":"10.3109\/13506129.2015.1135792"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Milandri A, Farioli A, Gagliardi C, Longhi S, Salvi F, Curti S, et al. Carpal tunnel syndrome in cardiac amyloidosis: Implications for early diagnosis and prognostic role across the spectrum of aetiologies. <i>Eur J Heart Fail<\/i> 2020; 22: 507\u2013515.","DOI":"10.1002\/ejhf.1742"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/4\/12\/4_CR-22-0110\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T03:55:24Z","timestamp":1670644524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/4\/12\/4_CR-22-0110\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-22-0110","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"article-number":"CR-22-0110"}}